Top in women’s health: Breast density guidance; drug implant for bothersome bleeding

In March, the FDA updated mammography regulations to include a lay language summary for patients on breast density reporting.

During a session at the ACOG Annual Clinical & Scientific Meeting, Christopher M. Zahn, MD, chief of clinical practice and health equity and quality at ACOG, reviewed the regulations and what they mean for patients and providers. It was the top story in women’s health last week.

Another top story was about new study results on a novel etonogestrel drug implant for women with bothersome bleeding. Researchers reported that 80% of people who received the implant experienced a satisfactory bleeding pattern.

Read these and more top stories in women’s health below:

Breast density reporting requirements change, clinical guidance remains unchanged

A late-breaking session at the ACOG Annual Clinical & Scientific Meeting highlighted FDA updates in breast density reporting that include a lay summarization for patients while ACOG clinical guidance on breast density remains unchanged. Read more.

Norethindrone effectively treats bothersome bleeding for women using etonogestrel implants

A novel etonogestrel drug implant demonstrated effectiveness in treating bothersome bleeding for women using etonogestrel implants for contraception, researchers reported. Read more.

Maternal age linked to readmission risk in women with preeclampsia, gestational hypertension

Maternal age in women with preeclampsia or gestational hypertension with severe features was associated with higher postpartum readmission risk, while intensive hypertension treatment at initial admission may limit risk. Read more.

COVID-19 vaccination does not reduce chance of pregnancy after intrauterine insemination

COVID-19 vaccination status did not significantly reduce the likelihood of becoming pregnant after intrauterine insemination, according to findings presented at the ACOG Annual Clinical & Scientific Meeting. Read more.